$TGTX Recent Headlines Dow industrials take fl

$TGTX Recent Headlines

Dow industrials take flight, rally to uncharted territory 10:31 a.m. Sept. 19, 2014 - Michael Ashbaugh

TG doubles down on PI3K inhibitor 8:33 a.m. Sept. 23, 2014 - Seeking Alpha
TG Therapeutics Reaches Phase 3 Special Protocol Assessment Faster Than Expected 9:44 a.m. Sept. 19, 2014 - Seeking Alpha
TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape 9:46 a.m. Sept. 18, 2014 - Zacks.com
Investors Should Exercise Caution With REVO Biologics IPO 8:22 a.m. Sept. 16, 2014 - Seeking Alpha
TG Therapeutics (TGTX) Weak On High Volume 10:01 a.m. Sept. 15, 2014 - TheStreet.com
Three Biotechs Ready to Partner Up 10:30 a.m. Sept. 8, 2014 - Barrons.com
TG Therapeutics (TGTX) Worth Watching: Stock Up 9.1% - Tale of the Tape 8:44 a.m. Sept. 4, 2014 - Zacks.com
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog 5:10 p.m. Aug. 18, 2014 - Zacks.com
Falling Earnings Estimates Signal Weakness Ahead for TG Therapeutics (TGTX) - Tale of the Tape 8:27 a.m. Aug. 8, 2014 - Zacks.com
Ligand: Pipeline Breakdown Reveals Bullish Outlook 9:12 a.m. July 30, 2014 - Seeking Alpha
10-Q: TG THERAPEUTICS, INC. 4:38 p.m. July 24, 2014 - Edgar Online - (EDG = 10Q, 10K)
TG Therapeutics' (TGTX) CEO Mike Weiss on Q2 2014 Results - Earnings Call Transcript 2:56 p.m. July 22, 2014 - Seeking Alpha
TG Therapeutics (TGTX) in Focus: Stock Moves 10.4% Higher - Tale of the Tape 9:25 a.m. July 3, 2014 - Zacks.com
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog 4:30 p.m. June 25, 2014 - Zacks.com
TG Therapeutics (TGTX) is Overbought: Is A Drop Coming? - Tale of the Tape 9:19 a.m. June 25, 2014 - Zacks.com
Strength Seen in TG Therapeutics, Inc. (TGTX) as Stock Rallies 12.94% - Tale of the Tape 8:44 a.m. June 24, 2014 - Zacks.com
A new partnership to develop IRAK-4 inhibitors 7:41 a.m. June 24, 2014 - Seeking Alpha
TG Therapeutics (TGTX) Crumbles: Stock Falls by 6.6% - Tale of the Tape 8:41 a.m. June 19, 2014 - Zacks.com
TG Therapeutics (TGTX) Catches Eye: Stock Surges 20.8% in Session - Tale of the Tape 8:37 a.m. June 13, 2014 - Zacks.com
Interim Phase 2 results for TG Therapeutics' cancer mAb 7:48 a.m. June 13, 2014 - Seeking Alpha


Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor 9:01 a.m. Sept. 23, 2014 - GlobeNewswire
TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202 7:31 a.m. Sept. 23, 2014 - GlobeNewswire
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia 7:01 a.m. Sept. 15, 2014 - GlobeNewswire
UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference 4:29 p.m. Sept. 8, 2014 - GlobeNewswire
TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference 9:26 a.m. Sept. 8, 2014 - GlobeNewswire
TG Therapeutics Announces Novel "Chemo-free" Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies 7:30 a.m. Aug. 15, 2014 - GlobeNewswire
TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas 4:06 p.m. July 21, 2014 - GlobeNewswire
TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update 4:06 p.m. July 21, 2014 - GlobeNewswire
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 4:27 p.m. July 15, 2014 - PR Newswire - PRF
Technical Updates, License Agreements, and Acquisitions - Analyst Notes on Incyte, BioMarin, Arrowhead, Ligand and Techne 5:50 a.m. July 8, 2014 - PR Newswire - PRF
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 6:40 a.m. June 27, 2014 - PR Newswire - PRF
TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4 8:09 a.m. June 24, 2014 - GlobeNewswire
Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 3:01 a.m. June 24, 2014 - BusinessWire - BZX
TG Therapeutics, Inc. to Present at the 2014 JMP Securities Healthcare Conference 8:31 a.m. June 23, 2014 - GlobeNewswire
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics 5:30 a.m. June 17, 2014 - PR Newswire - PRF
TG Therapeutics, Inc. to Present at the 2014 Wells Fargo Healthcare Conference 4:30 p.m. June 16, 2014 - GlobeNewswire
TG Therapeutics' TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) 5:31 a.m. June 13, 2014 - GlobeNewswire
Coronado Biosciences Announces February Inducement Award 4:06 p.m. May 9, 2014 - GlobeNewswire
TG Therapeutics, Inc. Provides Update on a Modified TGR-1202 Formulation and Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure 8:32 a.m. May 8, 2014 - GlobeNewswire
TG Therapeutics, Inc. to Present at the 39th Annual Deutsche Bank Healthcare Conference 8:32 a.m. May 5, 2014 - GlobeNewswire